VistaGen Therapeutics (VTGN) PT Raised to $7 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Price: $0.17 --0%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Join SI Premium – FREE
Jefferies analyst Andrew Tsai raised the price target on VistaGen Therapeutics (NASDAQ: VTGN) to $7.00 (from $6.00) while maintaining a Buy rating.
You May Also Be Interested In
- Goldman Sachs Downgrades China Southern Airlines Co Ltd. (600029:CH) to Sell
- Fabrinet (FN) PT Lowered to $364 at B.Riley, Stays Sidelined on Valuation
- Sigma Foods SAB DE CV (SIGMAFA:MM) PT Raised to Peso23 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
